US Stock MarketDetailed Quotes

CRIS Curis

Watchlist
  • 16.0816
  • -0.4284-2.59%
Trading May 3 10:36 ET
94.79MMarket Cap-1794P/E (TTM)

About Curis Company

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Company Profile

SymbolCRIS
Company NameCuris
Listing DateAug 1, 2000
Founded2000
CEOMr. James E. Dentzer
MarketNASDAQ
Employees49
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
AddressBuilding C,128 Spring Street,Suite 500
CityLexington
ProvinceMassachusetts
CountryUnited States of America
Zip Code02421
Phone1-617-503-6500
Websitehttp://www.curis.com

Company Executives

  • Name
  • Position
  • Salary
  • James E. Dentzer
  • Director, President and Chief Executive Officer
  • 1.66M
  • Diantha Duvall
  • Chief Financial Officer and Principal Accounting Officer
  • 1.01M
  • Jonathan B. Zung, PhD
  • Chief Development Officer
  • 882.42K
  • Martyn D. Greenacre
  • Chairman of the Board
  • 158.70K
  • Dr. Marc Rubin,M.D.
  • Independent Director
  • 123.70K
  • Dr. Kenneth I. Kaitin,PhD
  • Independent Director
  • 126.20K
  • Dr. John A. Hohneker, M.D.
  • Independent Director
  • 106.20K
  • Dr. Anne E. Borgman, M.D.
  • Independent Director
  • 103.70K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg